NEWS & MEDIA

Awards

Kura Oncology Named 2025 Fierce 50 Honoree

Awards

Kura CMO Mollie Leoni Featured as In Vivo 2025 Rising Leader

Awards

2025 Scrip Awards Deal of the Year Finalist

Awards

Kura CEO Troy Wilson Named an EY Entrepreneur Of The Year^® 2025 Pacific Southwest Award Winner

Kura Kommentary

Progress By Collaboration: The Development of Kura’s Menin Inhibitor for AML Research

Awards

Achievement in Operational Excellence to Deliver Business Transformation

Media Coverage

Asking the Right Questions in R&D

Media Coverage

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Media Coverage

Scrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

Kura Kommentary

Thank You, From Kura Oncology

Kura Kommentary

AML World Awareness Day and Kura’s Commitment

Awards

SDUT San Diego Top Workplaces 2024

Kura Kommentary

From Lab to Clinic: The Origin and Journey of Menin Inhibitors for AML Research

Awards

PharmaVoice 100 Top Industry Leaders: Kathy Ford

Awards

2024 Scrip Awards Community Partnership of the Year: Kura Oncology and Life Science Cares

2024 Scrip Awards Executive of the Year: Troy Wilson, Ph.D., J.D.

Awards

Kura Makes Fast Company’s 100 Best Workplaces for Innovators List

Kura Kommentary

Breakthrough Therapy Designation Granted for Ziftomenib in R/R NPM1-Mutant AML

Media Coverage

Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni, Kura Oncology

Life at Kura

Kura Oncology Supports Life Science Cares’ “Food is Medicine” Initiative

Media Coverage

Menin inhibitors seek to debut as newest targeted therapy for leukaemia

Kura Kommentary

Accelerating Bio Innovation 2024

Kura Kommentary

AML World Awareness Day 2024

Awards

2024 Citeline Awards Excellence in Patient Recruitment & Engagement

Media Coverage

Moving Forward, Giving Back: The ROI of Social Impact

Kura Kommentary

Kura CEO Troy Wilson on the Inflation Reduction Act

Life at Kura

Kura Core Values

Media Coverage

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Media Coverage

Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Media Coverage

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

Media Coverage

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Media Coverage

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Media Coverage

Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast

Media Coverage

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

Media Coverage

The Promise of Precision Oncology, Troy Wilson, President & CEO, Kura Oncology

Awards

SDUT San Diego Top Workplaces 2023

Media Coverage

Kura Oncology’s CEO gives an update on Q3 earnings

Awards

2023 Scrip Awards Best Oncology R&D Advance

Awards

PharmaVoice 100 Top Industry Leaders: Teresa Bair, J.D.

Kura Kommentary

CEO Troy Wilson On Giving Back: Empowering Young Minds to Explore Life Sciences

Awards

San Diego Business Journal Leaders of Influence in Life Science 2023 Honorees

Awards

San Diego Business Journal CEO of the Year Awards 2023 Finalists

Kura Kommentary

World Medical Innovation Forum Panel on The Innovation Gap: The Promise of Precision Oncology for Liquid Tumors

Kura Kommentary

What pharma can teach biotech about the life cycle management of a drug

Kura Kommentary

Kura Oncology 2022 Annual Report

Awards

The Medicine Maker Power List 2023: Francis Burrows

Life at Kura

The History and Culture of Kura

Media Coverage

Navigating Dose Optimization Requirements as a Small Biotech

Awards

SDUT San Diego Top Workplaces 2022

Media Coverage

Liquid Biopsies Guide the Development of Cancer Drugs

Life at Kura

COO Kathy Ford on What Makes Kura a Top Workplace

Awards

SDUT San Diego Top Workplaces 2021

Media Coverage

FDA’s Renewed Focus on Oncology Dosing Spooks Investors, but Companies Say They’re Ready

Media Coverage

Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations

Media Coverage

Is This the Dawn of Precision Oncology in Head and Neck Cancer?

Kura Kommentary

CEO Troy Wilson on Sailing Through the Storm: Lessons from the Pandemic

Awards

PharmaVoice 100: Innovator’s Journey

Awards

PharmaVoice 100: Entrepreneurs

Media Coverage

BIO: Kura Oncology CEO Wilson on the power of biotech in the quest beyond KRAS

Kura Kommentary

CEO Troy Wilson on Navigating a Clinical Stage Biopharmaceutical Company Through the Pandemic